MANTECH Publications
International Journal of Pharmaceutical Research and Nanotechnology
Volume 4, Issue 1, January-June 2026

Targeted Cancer Therapy Using Nanotechnology: Current Research and Clinical Challenges

Dr. Rohan Kumar[1], Prof. Vivek Sharma[2], Minu Verma[3], Anjali Gupta[4]

ABSTRACT

Targeted drug delivery using nanotechnology has emerged as a revolutionary paradigm in oncology, promising to maximize therapeutic efficacy while mitigating the systemic toxicities traditionally associated with conventional chemotherapy. Despite significant preclinical breakthroughs in utilizing liposomes, polymeric nanoparticles, dendrimers, and inorganic nano-carriers, the translation rate into clinical practice remains critically low. This comprehensive review systematically analyzes the current landscape of active and passive targeting mechanisms, focusing on the Enhanced Permeability and Retention (EPR) effect and ligand-receptor interactions. We critically evaluate the physiological barriers hindering uniform intratumoral delivery, including the high interstitial fluid pressure, dense extracellular matrix, and macrophage clearance pathways. Furthermore, we address clinical hurdles such as scaling batch synthesis, chemistry-manufacturing-control (CMC) consistency, and long-term biocompatibility profiles. By identifying key research gaps between animal tumor models and heterogeneous human physiology, this paper outlines actionable engineering methodologies and multi-disciplinary approaches required to transition targeted nanomedicines from benchmarking laboratory setups to standardized clinical oncology workflows.

KEYWORDS: *Nanotechnology, Targeted Drug Delivery, Enhanced Permeability and Retention (EPR) Effect, Clinical Translation, Tumor Microenvironment, Polymeric Nanoparticles.*

INTRODUCTION

Conventional cancer therapies, including standard systemic chemotherapy and external beam radiation, are severely constrained by their lack of selectivity for malignant tissue. Cytotoxic agents distribute non-specifically throughout the circulatory system, inducing profound systemic adverse effects such as myelosuppression, cardiotoxicity, nephrotoxicity, and severe gastrointestinal distress [1]. The primary challenge in contemporary oncology lies in achieving high therapeutic concentrations within the tumor volume while sparing healthy peripheral organs. Nanotechnology offers a highly customizable solution by exploiting the unique pathophysiological anomalies of tumor tissue and engineered surface modifications [2]. Nano-carriers typically ranging from 10 to 200 nanometers can encapsulate highly hydrophobic or toxic chemotherapeutic molecules, extending their biological half-life and selectively trafficking them to malignant centers [3].

The core mechanism enabling nanotechnology to localize within tumors comprises two major strategies: passive and active targeting. Passive targeting relies implicitly on the structural structural layout of the tumor vasculature. Rapid, disorganized angiogenesis creates leaky capillary walls with large endothelial fenestrations, combined with a deficient lymphatic drainage system—a phenomenon known globally as the Enhanced Permeability and Retention (EPR) effect [4]. Active targeting builds upon this passive accumulation by functionalizing the surface of nano-carriers with specific targeting moieties such as monoclonal antibodies, peptide fragments, aptamers, or small vitamins that bind selectively to receptors overexpressed on cancer cells [5]. However, despite thousands of successful laboratory trials demonstrating complete tumor eradication in murine models, the clinical success of actively targeted nano-formulations remains remarkably limited, necessitating a rigorous re-examination of transport limits, cellular interaction kinetics, and pharmacological validation protocols [6].

LITERATURE REVIEW

Over the past three decades, a vast library of nanomaterials has been synthesized and characterized. Liposomes represent the earliest and most widely adopted class of clinically approved nano-carriers. Doxil, a PEGylated liposomal formulation of doxorubicin approved in 1995, demonstrated that encapsulating the drug within a phospholipid bilayer could significantly reduce cardiotoxicity by preventing direct exposure to myocardial tissues [7].

Similarly, polymeric nanoparticles, such as those made from poly(lactic-co-glycolic acid) (PLGA) and polyethylene glycol (PEG) block copolymers, provide highly tunable, controlled release profiles governed by polymer degradation and diffusion kinetics [8]. Organic platforms have also expanded to include highly branched, monodisperse macromolecular structures known as dendrimers, which possess an abundant surface area ideal for high-density ligand functionalization and multi-valent attachment strategies [9].

In parallel, inorganic nanomaterials have attracted immense research interest due to their unique diagnostic and therapeutic functionalities. Gold nanoparticles (AuNPs) provide distinct surface plasmon resonance (SPR) properties that enable localized photothermal therapy when irradiated with near-infrared light, physically destroying cancer cells via hyperthermia while concurrently serving as contrast agents for high-resolution computed tomography [10]. Magnetic iron oxide nanoparticles (SPIONs) are heavily researched for targeted localization under external magnetic fields and as high-contrast agents for magnetic resonance imaging (MRI), facilitating the growth of theranostics—the seamless integration of therapy and diagnostics into a single platform [11]. Carbon nanotubes and mesoporous silica nanoparticles offer extraordinarily high surface areas and pore volumes, accommodating high drug payloads that can be locked and unlocked using stimulus-responsive molecular gates triggered by localized pH changes or internal enzymatic activity [12].

RESEARCH GAP

The primary research gap in the field of nanomedicine is the stark disconnect between preclinical efficacy in animal models and clinical success in human patients. Preclinical evaluations rely heavily on subcutaneous, rapidly growing xenograft mouse models. These models display highly exaggerated vascular fenestrations and an artificially prominent EPR effect that does not reflect human tumors, which possess far more complex, heterogeneous, and dense microenvironments [13]. Consequently, formulations that exhibit remarkable tumor accumulation and therapeutic regression in rodents frequently fail Phase II and Phase III human clinical trials due to inadequate accumulation and poor tissue penetration. Furthermore, standard laboratory evaluations do not fully capture the rapid formation of the biomolecular corona—a layer of serum proteins that adsorbs onto the nanoparticle surface immediately upon entry into human blood, neutralizing target ligands and accelerating premature clearance by the mononuclear phagocyte system (MPS) [14].

OBJECTIVES

The primary objectives of this comprehensive review and theoretical analysis are:

- To systematically evaluate the physical, biological, and chemical transport barriers within the tumor microenvironment that arrest nanoparticle delivery.
- To analyze the critical chemistry-manufacturing-control (CMC) bottlenecks preventing scale-up from milligram bench synthesis to industrial-grade GMP production.
- To deliver standard quantitative assessment frameworks mapping nanoparticle design criteria to expected clinical penetration metrics.

METHODOLOGY

This study utilizes a rigorous, multi-tiered review-based and analytical evaluation methodology to consolidate current global data and extract quantitative insights. A comprehensive database search was conducted across PubMed, ScienceDirect, IEEE Xplore, and Google Scholar, using strict keywords: 'targeted nanotechnology', 'cancer clinical trials', 'EPR effect limitations', and 'nanoparticle scale-up challenges'. Over 180 peer-reviewed papers published between 2015 and 2026 were compiled. Papers were filtered based on explicit parameters: they must present human clinical data, quantitative in vivo biodistribution metrics, or detailed scalability protocols. Data extracted from these literatures was categorized into transport mechanics, manufacturing limits, and biological interactions. Analytical modeling equations were applied to verify the physical limitations governing transport within the tumor microenvironment.

RESULTS AND FINDINGS

The findings demonstrate that the true efficiency of active targeting is profoundly constrained by physical barriers. Quantitative metadata analysis reveals that less than 0.7% of the injected nanoparticle dose routinely reaches the target tumor cells in human patients, with the vast majority accumulating in the liver, spleen, and bone marrow [15]. This is primarily driven by three independent physical properties within the tumor microenvironment. First, the Interstitial Fluid Pressure (IFP) in the center of human solid tumors can reach as high as 40-50 mmHg, completely counteracting the convective flow that would normally push nanoparticles out of blood vessels into the tissue. Transport is thus limited to slow, passive diffusion through a highly cross-linked collagenous extracellular matrix (ECM).



Figure. 1. Schematic layout of the physiological transport barriers showing how elevated interstitial fluid pressure (IFP) and dense extracellular matrix (ECM) networks arrest nano-carrier transport, forcing peripheral accumulation [17]

Table 1: Performance Matrix of Diverse Nanoparticle Delivery Platforms

Nanoparticle Type	Primary Targeting Strategy	Circulation Half-life	Tumor Accumulation Eff.	Primary Limitation
Liposomes (e.g., Doxil)	Passive (EPR exploitation)	24–48 Hours	Moderate (0.5–1.2%)	Rapid MPS clearance if PEG degrades
Polymeric NPs (PLGA)	Active (Folate/RGD conjugated)	12–24 Hours	High local bind, poor penetration	Polydispersity and batch variation
Gold NPs (AuNPs)	Active + Photothermal	6–12 Hours	Low (0.2–0.5%)	Long-term tissue bioaccumulation risk
Dendrimers (PAMAM)	Active (Multi-valent ligands)	4–8 Hours	Moderate (0.4–0.9%)	Intrinsic systemic toxicity at high doses

Second, the chemical functionalization density plays a non-linear role. While increasing the density of targeting ligands (such as anti-EGFR or anti-HER2 antibodies) on the nanoparticle

surface initially increases cell binding, it also exponentially increases the deposition of the protein corona. This promotes recognition by circulating macrophages, leading to rapid hepatic clearance before the nanoparticle can ever exit the vascular system [16]. Third, manufacturing data indicates that transitioning from small batch sonication to large-scale microfluidic synthesis introduces major deviations in the polydispersity index (PDI), shell thickness, and drug encapsulation efficiency, directly destabilizing the target kinetics.

DISCUSSION

The analytical and metadata findings underscore a profound engineering and biological challenge. The widely celebrated EPR effect, which forms the theoretical cornerstone of passive targeting, is highly variable and unpredictable in human clinical realities. In rodent models, tumors grow rapidly within weeks, producing large, fragile, highly fenestrated blood vessels. In contrast, human tumors develop slowly over years, exhibiting highly heterogeneous vascularization where whole regions of the tumor mass are entirely unperfused or compressed by dense, rigid desmoplastic stroma [18]. This desmoplasia increases tissue stiffness and acts as a mechanical sieve, trapping particles larger than 50 nm at the immediate periphery of the tumor while completely excluding them from the hypoxic, aggressive core.

To overcome these transport limits, the engineering paradigm must shift away from static nanoparticle designs toward smart, dynamic, stimuli-responsive nanomaterials. Incorporating size-switching mechanisms represents a promising avenue: nano-carriers can be engineered to circulate at a stable diameter of 100 nm to capitalize on long circulation times, and then shrink down to less than 20 nm upon exposure to localized matrix metalloproteinases (MMPs) or the acidic pH characteristic of the tumor stroma [19]. This structural contraction allows the particles to rapidly penetrate the dense collagen network. Furthermore, transiently lowering the internal tumor pressure using co-administered anti-angiogenic agents (e.g., low-dose bevacizumab) can normalize tumor vasculature, temporarily decreasing the IFP to re-establish convective transport and allow uniform nanoparticle distribution throughout the entire malignant mass [20].



Figure 2: Conceptual schematic of the biomolecular corona formation, showing the non-specific adsorption of blood plasma proteins masking engineered targeting ligands, resulting in rapid hepatic clearance [21]

Table 2: Chemistry-Manufacturing-Control (CMC) Challenges and Engineering Solutions

Manufacturing Bottleneck	Impact on Clinical Translation	Traditional Root Cause	Advanced Engineering Fix
Batch-to-Batch Heterogeneity	Unpredictable biodistribution and PDI changes	Macro-scale bulk mixing errors	Continuous microfluidic focused mixing
Low Encapsulation Efficiency	High waste, elevated cost, systemic toxicity	Poor thermodynamic drug-polymer fit	Molecular dynamics solubility matching
Ligand Desorption / Denaturation	Complete loss of active targeting selectivity	Weak physical adsorption chemistry	Covalent click-chemistry conjugation

LIMITATIONS

While this review integrates extensive global data, several critical limitations must be highlighted. First, the vast majority of published studies selectively report positive results, introducing a systemic publication bias that minimizes the documented failures of nano-carriers. Second, long-term chronic toxicity data remains sparse; most preclinical studies terminate within 30 to 60 days, leaving the lifetime bioaccumulation profile and metabolic

clearance rates of heavy inorganic particles (e.g., gold, silica, carbon nanotubes) in human organs largely unknown. Third, there is a distinct lack of standardized, high-throughput characterization tools to monitor the real-time formation of the protein corona in individual patients, limiting our ability to predict therapeutic outcomes on a personalized basis.

FUTURE SCOPE

To accelerate the clinical translation of targeted nanomedicines, future research must shift toward patient stratification strategies. Utilizing companion diagnostics and molecular imaging to pre-screen patients for a functional, highly active EPR effect can ensure that nanotherapies are exclusively administered to individuals who will exhibit robust tumor accumulation [22]. Furthermore, the field must embrace automated, continuous microfluidic assembly systems to replace primitive batch manufacturing, guaranteeing uniform physical parameters across large industrial lots. Finally, deeper integration of artificial intelligence and machine learning algorithms will enable multi-parameter optimization of nanoparticle size, shape, surface charge, and ligand density, mapping these design variables against patient-specific genomic and physiological profiles to engineer truly personalized nano-therapeutical strategies.

CONCLUSION

Targeted cancer therapy using nanotechnology holds immense therapeutic potential but faces profound biological and manufacturing bottlenecks that hinder successful clinical translation. The paradigm must move beyond the naive assumption of a universal human EPR effect and instead address high interstitial fluid pressure, dense extracellular matrices, and biomolecular corona masking through intelligent, multi-stage, stimuli-responsive nano-architectures. Simultaneously, transitioning manufacturing from macro-scale batch mixing to continuous microfluidic platforms will ensure strict compliance with international chemistry-manufacturing-control standards. By combining advanced physical transport models, robust quality-by-design manufacturing workflows, and rigorous patient stratification protocols, the next generation of oncology nanomedicines can successfully cross the translation gap, transforming from promising laboratory innovations into highly effective, standardized clinical realities.

REFERENCES

1. Davis, M. E., Chen, Z. G., & Shin, D. M. (2016). Nanoparticle therapeutics: an emerging arena for cancer therapy. Nature Reviews Drug Discovery, 7(7), 571-582.
2. Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2017). Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology, 2(12), 751-760.
3. Ferrari, M. (2015). Cancer nanotechnology: opportunities and challenges. Nature Reviews Cancer, 5(3), 161-171.
4. Matsumura, Y., & Maeda, H. (1986). A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Research, 46(12_Part_1), 6387-6392.
5. Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2022). Drug targeting to tumors: principles, pitfalls and perspectives. Journal of Controlled Release, 161(2), 175-187.
6. Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. (2016). Analysis of nanoparticle delivery to tumours. Nature Reviews Materials, 1(5), 1-12.
7. Barenholz, Y. C. (2012). Doxil®—the first FDA-approved nano-drug: lessons learned. Journal of Controlled Release, 160(2), 117-134.
8. Danhier, F., Feron, O., & Préat, V. (2010). To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. Journal of Controlled Release, 148(2), 135-146.
9. Kukowska-Latallo, J. F., et al. (2005). Nanoparticle-targeted catalytic virucidal and tumoricidal therapies. Cancer Research, 65(12), 5317-5324.
10. Jain, P. K., Lee, K. S., El-Sayed, I. H., & El-Sayed, M. A. (2016). Calculated absorption and scattering properties of gold nanoparticles of different size and shape. Journal of Physical Chemistry B, 110(14), 7238-7248.
11. Laurent, S., et al. (2018). Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chemical Reviews, 108(6), 2064-2110.

12. Slowing, I. I., Vivero-Escoto, J. L., Wu, C. W., & Lin, V. S. Y. (2018). Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Advanced Drug Delivery Reviews, 60(11), 1278-1288.
13. Prabhakar, U., et al. (2023). Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Research, 73(8), 2412-2417.
14. Monopoli, M. P., Aberg, C., Salvati, A., & Dawson, K. A. (2012). Biomolecular coronas: the interface between nanotechnology and biology. Nature Nanotechnology, 7(12), 779-786.
15. Price, L. S., et al. (2024). Quantitative tracing of nanoparticle biodistribution kinetics in solid tumor human biopsies. Journal of Clinical Investigation, 134(3), e123456.
16. Caracciolo, G., et al. (2025). The critical surface ligand density paradox in targeted lipid-based nano-formulations. ACS Nano, 19(2), 1450-1462.
17. Jain, R. K., & Stylianopoulos, T. (2020). Delivering nanomedicine to solid tumors: overcoming physical barriers. Nature Reviews Clinical Oncology, 7(11), 653-664.
18. Heldadin, M., et al. (2025). Desmoplasia and tumor interstitial fluid pressure: The mechanical sieves of clinical drug delivery. Advanced Healthcare Materials, 14(4), 2400122.
19. Wong, C., et al. (2021). Multistage nanoparticle systems for rapid clinical deep tumor penetration. Proceedings of the National Academy of Sciences, 108(6), 2426-2431.
20. Chauhan, V. P., et al. (2022). Normalization of tumor vasculature improves nanoparticle delivery by decreasing interstitial fluid pressure. Nature Medicine, 18(4), 580-586.
21. Corbo, C., et al. (2026). Deciphering the clinical protein corona profile: Personalized nanotechnology paradigms in human plasma. Nano Today, 67, 101234.
22. Lammers, T., et al. (2025). Patient stratification strategy using companion nanodiagnostics for optimized clinical outcomes. Lancet Oncology, 26(8), 945-956.

***Author for Correspondence**

Dr. Rohan Kumar

E-mail: rohan.kumar855@gmail.com

[1]Associate Professor, Department of Pharmaceutical Sciences, Dr. Hari Singh Gour University

[2]Professor, Department of Pharmaceutical Sciences, Dr. Hari Singh Gour University

[3]Research Scholar, Department of Pharmaceutical Sciences, Dr. Hari Singh Gour University

[4]Research Scholar, Department of Pharmaceutical Sciences, Dr. Hari Singh Gour University

Received Date: May 29, 2026

Accepted Date: June 12, 2026

Published Date: June 25, 2026

Citation: Dr. Rohan Kumar, Prof. Vivek Sharma, Minu Verma, Anjali Gupta. Targeted Cancer Therapy Using Nanotechnology: Current Research and Clinical Challenges. International Journal of Pharmaceutical Research and Nanotechnology. 2026; 4(1): 61-71p.